Sanger spinout gets $10M, tackles the microbiome frontier; Adaptimmune and Bellicum partner T cell tech
The Sanger Institute has launched a new spinout dubbed Microbiotica, which is leaping into the hot microbiome field. The IP Group and Cambridge Innovation Capital are bankrolling the startup with $10 million and what’s billed as “one of the world’s most extensive collections of cultured human gut bacteria with associated genome analysis, along with humanized models for the development of therapeutics based on live bacteria.” Microbiotica plans to establish labs within the Wellcome Genome Campus at Hinxton, Cambridge.
The UK’s Adaptimmune Therapeutics $ADAP has decided to collaborate with Bellicum $BLCM on T cell therapies. They’ll be using Bellicum’s GoTCR technology (inducible MyD88/CD40 co-stimulation, or iMC) with Adaptimmune’s affinity-optimized SPEAR T-cells for the potential to “create enhanced TCR product candidates. Depending on results from the preclinical proof-of-concept phase, the companies expect to progress to a two-target co-development and co-commercialization phase.”
The new CEO at Concordia International (CRX:TO) has decided to halt a Phase III study of Photodynamic Therapy with Photofrin, which they say is “reflective of some of the challenges the Company experienced enrolling the trial for a rare disease that affects a relatively small patient population.”
Purdue and Shionogi have hatched a plan to jointly launch and commercialize Symproic, including a “comprehensive collaboration on all aspects of strategy, sales, and other activities.”